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Abstract 
Patients with liver cirrhosis often exhibit sleep-wake abnormalities, which are, at least to some 
extent, circadian in origin. A relatively novel non-pharmacological approach to circadian disruption 
is appropriately timed bright light therapy. The aims of this pilot study were to investigate sleep-
wake characteristics of a well-characterized population of inpatients with cirrhosis, and to evaluate 
the efficacy of bright light therapy in the hospital setting. Twelve consecutive inpatients with 
cirrhosis underwent complete sleep-wake assessment, to include qualitative and semi-quantitative 
(actigraphic) indices of night-time sleep quality, daytime sleepiness, diurnal preference, habitual 
sleep timing, quality of life, mood and circadian rhythmicity [i.e. urine collections for measurement 
of the melatonin metabolite 6-sulphatoxymelatonin (aMT6s)]. Patients showed extremely impaired 
night sleep quality (Pittsburg Sleep Quality Index global score: 16.3±2.1) and daytime sleepiness 
was common (Epworth Sleepiness Scale: 8.3±3.2). Five patients were randomly assigned to a single 
room in which lighting was controlled in relation to timing, spectral composition and intensity 
(lights on at 06:30 and off at 22:30, blue-enriched, more intense light in the morning, red-enriched, 
less intense light in the afternoon/evening); the others stayed in identical rooms with standard 
lighting. Sleep diaries revealed poor sleep quality, prolonged sleep latency (67±138 min) and a 
reduced sleep efficiency (69±21%). These features were confirmed by actigraphy (sleep efficiency: 
71±13%; fragmentation index: 55±15%). Quality of life was globally impaired, and mood 
moderately depressed (Beck Depression Inventory: 19.4±7.9). Seven patients underwent serial urine 
collections: no circadian aMT6s rhythm was detected in any of them, neither at baseline, nor during 
the course of hospitalization in either room (n=4). In conclusion, sleep and circadian rhythms in 
hospitalized, decompensated patients with cirrhosis are extremely compromised. Treatment with 
bright light therapy did not show obvious, beneficial effects, most likely in relation to the severity 
of disturbance at baseline. 
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Introduction 
Up to 50-65% of patients with cirrhosis of the liver complain of sleep-wake disturbances, mainly 
delayed sleep-wake habits, increased sleep latency and sleep fragmentation. These are considerably 
more common in patients with cirrhosis compared to patients with other chronic diseases, for 
example renal failure [1]. Less information, however, is available on the sleep-wake profile of 
hospitalized, very decompensated patients with cirrhosis [2, 3]. 
Sleep-wake rhythms are regulated by the interaction of two processes: the homeostatic one, 
which is a pressure system (i.e. the longer the wake period, the higher the likelihood of falling 
asleep) and a circadian one, which is regulated by the circadian timing system and light-dark cycle 
[4]. While limited data are available onthe homeostatic regulation in patients with cirrhosis, their 
circadian timing system has been studied in some depth. These patients exhibit delayed melatonin 
rhythms, in association with delayed sleep habits, which are probably due to a combination of 
impaired sensitivity to light and delayed hepatic melatonin metabolism [5-7]. This type of circadian 
disturbance is not unlike jet-lag East, or delayed sleep phase syndrome (DSPS), a condition 
characterized by sleep onset and wake times that are considerably delayed relative to conventional 
sleep-wake times [8]. Patients with this syndrome find it difficult to initiate sleep before 02:00 h 
and, when free of societal constraints, wake between 10:00 h and 13:00 h. Enforced, conventional 
wake times can result in chronically insufficient sleep, excessive day-time sleepiness and, 
ultimately, impaired night sleep quality [9]. As for a traveler flying East, the goal of DSPS 
treatment is advance of the circadian clock to entrain to the 24 h light-dark cycle by chronotherapy: 
bright light administration in the morning, with/without administration of exogenous melatonin in 
the evening.  
Chronotherapy has been formally studied and shown to be beneficial in well-defined 
populations, such as shift workers [10, 11], subjects with jet-lag [12] and, as previously mentioned, 
patients with DSPS [8]. In patients with cirrhosis, the use of evening melatonin may not be safe due 
to the known impairment in melatonin metabolism, which could cause accumulation of exogenous 
melatonin and high morning/daytime melatonin levels, which may worsen rather than improve 
these patients’ condition [13]. By contrast, morning bright light administration may be a reasonable 
option in this patient population.  
The efficacy of bright light administration relates to: a) time of administration; b) intensity; 
c) spectral composition and d) dynamics, i.e. how these features change across time of day. The 
importance of the spectral composition is due to the fact that intrinsically photosensitive retinal 
ganglion cells (ipRGCs), which are non rod- non cone-photoreceptors and contribute less to image 
formation, contain a photopigment called melanopsin. Melanopsin containing ipRGCs are 
maximally stimulated by light of wavelengths between 460 and 500 nm, and are considered largely 
responsible for circadian entrainment [14, 15]. Therefore, in recent years, studies have been devoted 
to testing the effects of blue-enriched versus standard light as a chronotherapeutic agent [16]. 
The aim of the present, pilot study was to investigate sleep-wake characteristics and 
circadian rhythms in decompensated inpatients with cirrhosis, and to assess the effect of 
appropriately timed blue-enriched light therapy in this population. 
Patients and Methods 
Twelve consecutive, medicated inpatients with cirrhosis of the liver (9 males, age±SD: 59±15 
years) admitted to the Regional Centre for Liver Diseases of the Department of Medicine of Padova 
University Hospital were enrolled. Of these, 4 (all males, age±SD: 54±5 years) were hospitalized 
for more than 10 days. Two of the 12 patients (17%) had a urinary catheter, and 3 (25%) had a 
diaper, and were thus unable to collect urine (vide infra); 8 (67%) of the patients were on loop 
diuretics. Diagnosis of cirrhosis was clinical, biochemical, radiological and, where necessary, 
histological. Patients were classified in relation to the severity of hepatic disease, based on both the 
Child-Pugh [17] and MELD [18] scores. Exclusion criteria were specific, diagnosed sleep-wake 
disturbances (i.e. obstructive sleep apnea or restless legs syndrome), shift work, and/or treatment 
with psychoactive drugs or drugs known to affect sleep/melatonin metabolism. The study was 
conducted between October and May, to avoid the confounding effect of the sunny summer months.  
 
Night-time sleep quality 
The Pittsburg Sleep Quality Index (PSQI) evaluates subjective sleep quality during the previous 
month and can distinguish “good sleepers” from “poor sleepers”. It is a self-administered 
questionnaire based on 24 questions with 4 possible answers referring to 7 domains; the latter are 
scored from 0 to 3 (0=best). The PSQI total score is the sum of all domains, and a total score >5 
characterizes “poor sleepers” (range: 0-21) [19]. 
The Sleep Timing and Sleep Quality Sleep questionnaire (STSQS) allows collection of a 
subjective score of night sleep quality on a scale from 1 to 9 (1=best sleep ever, 9=worst sleep ever) 
and provides summary information on sleep-wake habits [20]. 
Actigraphy. An actigraph is a small device, similar to a wristwatch and worn on the non-dominant 
wrist, which records movement by use of an accelerometer. The simple assumption underlying the 
technique is wake=movement; sleep=lack of movement. Each inpatient wore an Actiwatch® 
(Cambridge Neurotechnology Ltd., Cambridge, UK) during the whole period of hospitalization. 
Data were then downloaded and analyzed by the software provided (Actiwatch Activity & Sleep 
Analysis 5’, version 5.10, Cambridge Neurotechnology Ltd., Cambridge, UK). The time period 
22.30-06.30 h was referred to as night (controlled lighting system off) and used for analysis. The 
following indices were extracted: actual sleep time, sleep latency (i.e. time to fall asleep), sleep 
efficiency (i.e. percentage of time spent sleeping out of the total time spent in bed), immobile time 
(%), total activity score, fragmentation index (an indicator of restlessness based on the ratio 
between the percentage time spent moving and the percentage immobility phases of over 1-min 
length) [21].  
 
Daytime sleepiness 
This was assessed both as habitual sleepiness in everyday life and instantaneous sleepiness at 
different times of the ongoing study.  
The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire in which patients are 
asked to assess their chance of dozing in eight different situations (0= would never doze; 3= high 
chance of dozing). Excessive daytime sleepiness is defined by a total score >11 (range:0-24) [22].  
The Karolinska Sleepiness Scale (KSS) is a self-administered scale in which patients rate their 
sleepiness over the previous 10 minutes on a 1-9 scale (1= very alert; 9= very sleepy, difficulty 
staying awake, fighting sleep) [23]. This was administered hourly, over the same period as the urine 
collections. 
 
Diurnal preference 
The Horne-Östberg (HÖ) questionnaire determines a subject’s diurnal preference (definitely 
morning [score 70–86], moderately morning [59–69], intermediate [42–58], moderately evening 
[31–41] and definitely evening [16–30]) based on 19 self-administered questions [24]. 
 
Usual sleep timing 
Patients completed daily Sleep Diaries during the whole length of their hospitalization. Information 
were collected on bed time, try to sleep time, sleep latency, number of awakenings, wake up time, 
get up time, number of daytime naps and their duration [25]. 
 
Health-related quality of life 
The SF-36 (V1) Standard is a generic health-related quality of life questionnaire providing an 
eight-scale profile, as well as two summary measures; it does not include questions on sleep 
behavior [26]. The response to each question is scored, the eight profiles summated and the data 
transformed to a scale of 0 (worst) to 100 (best). Summary scores were calculated using Italian 
coefficients [27]. 
The Chronic Liver Disease Questionnaire (CLDQ) is a disease-specific health-related quality of 
life questionnaire providing scores for six domains of functional health and well-being, and a 
summary score. The response to each question is scored on a scale of 1 (all of the time) to 7 (none 
of the time); defined scores sets are averaged within each domain. Four questions explore sleep–
wake behaviour and the responses to these are included in the Fatigue or Emotional Function 
domains [28]. The Italian version of the questionnaire was utilized [29]. 
 
Mood 
Beck Depression Inventory (BDI) is a scale that quantifies depression based on 21 statements, each 
of which is scored from 0 (best condition) to 3 (worst condition). The sum of such scores identifies 
minimal (score 0-9), slight (score 10-18), moderate (score 19-29) or severe (score 30-63) depression 
[30]. 
 
6-sulphatoxy-melatonin (aMT6s) rhythm 
Sequential urine samples were collected from patients over the first two nights after inpatient 
admission, and the day in between (4-hour intervals during the day and 8-hour intervals overnight, 
for a total of 36 hours) [31]; 3 ml aliquots were collected from each sample and kept at -20°C until 
assayed for 6-sulpahtoxymelatonin (aMT6s), in duplicate, using a commercial radioimmunoassay 
[32]. Urine collections were repeated every 7 days, depending on the length of hospitalization. All 
samples for a single individual were measured in the same assay. The aMT6s profiles were 
evaluated using cosinor analysis, which is based on the least square approximation of the time series 
using a cosine function with a period of 24 hours [33]. The following parameters were obtained: 
24h output: aMT6s excretion over 24 hours; acrophase time: time of the peak aMT6s concentration, 
or maximum of the fitted cosinor function; mesor: mean aMT6s value for all the samples included 
in the cosinor analysis, and amplitude: difference between the mesor and the peak aMT6s 
concentrations. The acrophase time was classified as normal if it occurred between midnight and 
06:00 [34]. The ‘goodness of fit’ used to determine the validity of the cosinor-derived indices was 
the likelihood of the data points fitting a straight line as opposed to a cosine curve, expressed as a p 
value; data were considered acceptable if the cosinor fit was significant at the 95% level (p < 0.05) 
[33].  
 
Light therapy 
Four adjacent single rooms were selected; all had the same dimensions and were situated on the 
same side of the ward corridor, facing North-North/West, on the ground floor of the hospital. In one 
of these, the standard wall-mounted lighting system switched on/off by the patient and/or personnel 
was replaced by a controlled lighting system (Amadea wall-mounted lamp, Derungs-Waldmann 
Illuminotecnica, San Giuliano Milanese, Italy). Two ballasts (39W) emitted light with varying 
spectrum (from 6500 K to 3000 K) and intensity. In order to advance the sleep-wake/circadian cycle 
of patients with cirrhosis, the lamp was set to automatically switch on at 06:30 h and off at 22:30 h. 
In addition, the lighting changed dynamically across the day, being more intense and blue-enriched 
in the morning (6500 K), and becoming less intense and red-enriched during the afternoon/evening 
hours (turning from 6500 K to 3000 K). The maximum intensity in the gaze direction was 500 lux. 
The patient/personnel could not operate the system; however, the room was equipped with an 
additional switch that would allow immediate and full lighting of the room in case of a medical 
emergency.  
Results 
Reasons for hospitalization were cirrhosis-related in 10 (83%) of the 12 patients: tense ascites 
(n=3), hepatic encephalopathy (3), hepato-renal syndrome (3), spontaneous bacterial peritonitis (1). 
One patient was admitted for cholecystitis and one for pneumonia. In relation to the degree of 
hepatic decompensation, 1 patient was classed as Child A, 1 as B, and 10 as C; average MELD 
score was 21±7. Five patients (42%) were randomized to the room with the controlled lighting 
system and the remaining seven patients to standard lighting rooms. Average inpatient stay was 
8.4±6.1 days. 
Eleven patients (92%) completed the STSQS and sleep diaries, 8 (67%) the ESS, BDI and 
SF-36, 6 (50%) the PSQI and HÖ, 5 (42%) the CLDQ. The remaining sets of questionnaires were 
not completed due to the severity of the condition and associated fatigue/tiredness. Hourly KSS 
compliance was even lower, with only 3 patients (25%) completing the scale but not on an hourly 
basis as required. 
No substantial differences were observed between cases and controls the intervention and 
control group patients in relation to age, hepatic decompensation, night-time sleep quality, daytime 
sleepiness, diurnal preference, quality of life and mood (Table 1). Sleep timing and actigraphy were 
also comparable (Table 1). Patients showed profoundly impaired sleep quality (PSQI global score: 
16.3±2.1, STSQS sleep quality: 6.3±2.5). They all had intermediate (50%) or moderately morning 
(50%) diurnal preference. Two (18%) had excessive daytime sleepiness (abnormal ESS). Sleep 
diaries were consistent with subjectively reported sleep disturbances, documenting prolonged sleep 
latency (67±138 min) and reduced sleep efficiency (69±21%). Sleep onset occurred at 23.7±2.2 h 
and wake up at 6.3±1.6 h with 3.4±1.8 awakenings per night. Actigraphic data also confirmed 
extremely disrupted sleep (sleep efficiency: 71±13%; fragmentation index: 55±15%) (Table 2). 
Quality of life was globally impaired and mood was moderately depressed (BDI: 19.4±7.9)(Table 
1). 
Baseline sequential 36 h urine collections were possible in 7 (3 in the room with controlled 
lighting system) out of the 12 patients. Four of these underwent a second sequential 36 h urine 
collection at 7 days from admission, and two a further one, at 14 days (Figure 1). No significant 
cosine fit was detected in any of the aMT6s profiles (Figure 1), thus cosinor analysis parameters are 
not presented. At baseline, average aMT6s output was 12.2 ±7.9 µg/24h, and was comparable in 
cases the intervention and control group (13.8±16.9 µg/24h vs. 10.6±5.7 µg/24h, p>0.05). No 
significant correlations were observed between aMT6s 24h output and serum creatinine levels. 
No significant differences were observed between the intervention and control rooms in the 
evolution of the patients’ sleep-wake profiles (diaries and actigraphy) over the length of 
hospitalization. However, wake-up times were earlier in patients admitted into the treatment room 
(Table 2). Bright, dynamic blue-enriched lighting had no obvious effects on the cosine fit of the 
aMT6s profiles (Figure 1), which remained not significant. However, visual analysis of the repeated 
aMT6s profiles suggested phase advance in two patients, who were both admitted into the 
controlled lighting system room (Figures 1D and 1G). 
Discussion 
Patients enrolled in the present study were severely decompensated, and exhibited profoundly 
impaired sleep-wake and circadian melatonin rhythms. Bright daytime blue-enriched light treatment 
did not have any obvious beneficial effects, most likely in relation to the severity of sleep/circadian 
disturbance at baseline. However, visual analysis of the sleep-wake profiles and the urinary aMT6s 
of the patients treated with light suggested some degree of phase advance, still within the context of 
aMT6s arrhythmia. 
In the group studied here, quality of life was poor, as previously observed by other authors 
[35-37], and possibly even worse, particularly in relation to the “physical” and “emotional role” 
domains, as well as the global health one, global physical health being worse than global mental 
health. These data are in agreement with previously published data from our own and from other 
authors, suggesting that the physical domains of quality of life are more affected than the mental 
domains in these patients [35, 36]. Mood was depressed, also in agreement with previously 
published work [38]. 
Patient compliance with the study procedures was poor, especially regarding actigraphy and 
to the repeated questionnaires, most likely due to their severely compromised clinical and 
psychological status. As previously observed, compliance was slightly better with simple, short 
questionnaires compared to the more complex ones [20]. Sleep questionnaires, sleep diaries and 
actigraphy all showed profoundly altered night-time sleep quality, with very prolonged sleep 
latency and extremely fragmented night sleep. All patients had morning/intermediate diurnal 
preference, thus the previously reported association between impaired sleep quality and eveningness 
in cirrhosis could not be studied in this group [1, 35].  
No significant cosine fit for the aMT6s rhythm was detected in any of the patients. We have 
previously reported [13] no detectable rhythm in 57% of decompensated outpatients with cirrhosis. 
The findings in the present study document 100% lack of rhythm. This could be a result of 
decompensation, medication and/or hospitalization. Urinary aMT6s 24h output, however, was 
similar to that described previously [13] and more recently by Chojnacki et al. [39], confirming 
desynchronization of melatonin/aMT6s timing rather than abnormal melatonin production in this 
patient population. These findings could relate to both decompensation of cirrhosis, as previously 
suggested [40], and also to the hospital environment, in which patients are often disturbed across 
the 24-hours in relation to drug and food delivery, and management of other patients who are in 
nearby rooms. In addition, there is a possibility that an abnormally late melatonin/aMT6s peak, 
which can be detected in decompensated patients with cirrhosis in very tightly controlled light 
conditions [5, 6] might have been suppressed by morning light, thus completely masking the 
underlying rhythm. Furthermore, kidney failure may have impinged on urinary aMT6s excretion, 
although the profiles of the two patients with hepato-renal syndrome did not seem different from the 
remaining five. In addition, a significant proportion of the patients were on diuretics. To our 
knowledge, no literature data are available on the effect of diuretics on the excretion of aMT6s or 
other melatonin metabolites. While we have not tested this directly in our study, the fact that aMT6s 
excretion was calculated as ngr per hour (as opposed to ngr per volume unit) should contain 
diuretics-related bias, if any. In addition no significant relationships were observed between daily 
aMT6s output and serum creatinine. Finally, since aMT6s is a small molecule, it should be freely 
excreted and probably not reabsorbed; this suggest that the influence of diuretics, and especially 
loop diuretics, should be limited. 
In this setting, the lack of an obvious effect of light administration is reasonable, as light can 
strengthen or shift an existing rhythm, but cannot restore an absent rhythm, which was the baseline 
situation for all the patients enrolled. However, visual analysis of the repeated aMT6s profiles 
suggested some degree of phase advance in two patients, both in the controlled lighting system 
room. We have previously documented a beneficial effect of bright light therapy in a patient with 
compensated cirrhosis of the liver and sleep-wake inversion [41]. Although aMT6s was not 
measured in this subject, she appeared to have some degree of sleep-wake rhythmicity, albeit 
abnormal. Other authors have utilized bright light administration in the hospital setting and have 
succeeded in increasing total sleep time and in decreasing night awakenings [42, 43]. In these 
studies, however, light intensity was higher, and the patient population was not as compromised 
from a medical standpoint. Riemersma-van der Lek et al. [44] found that light therapy and 
melatonin treatment in demented people ameliorated sleep architecture nocturnal restlessness, sleep 
efficiency and sleep fragmentation. We chose not to administer melatonin in addition to light, as we 
were concerned about a possible negative effect due to reduced/delayed hepatic metabolism [13]. 
The limitations of this study are several, including the small number of patients recruited, 
their only partial compliance with study procedures, and the use of actigraphy in substantially bed-
ridden individuals. However, these pilot data seem useful as: i) they help to highlight the difficulties 
of studying sleep-wake/circadian rhythms in a clinical setting [20, 45], and the need for more 
patient-friendly tools and study protocols; ii) they suggest that further, formal studies on the effects 
of chronotherapy in less decompensated outpatients with cirrhosis may be worthy. Finally, as there 
is limited interest for circadian rhythms and light hygiene in routine hospital medicine, the concept 
of adaptable lighting in the hospital setting is in itself an innovation, and may attract the attention of 
both doctors and health administrators.   
 
 
Figure legends 
Figure 1. Individual urinary aMT6s profiles over 36 h collections at baseline and, where available, 
during the hospitalization period (7 and 14 days [d 7/14]) in consecutive patients, as enrolled. Each 
point represents the middle time of the collection period. Each patient is briefly characterized in 
relation to origin/degree of decompensation of their cirrhosis, reason for hospital admission and 
room type. The levels of urinary aMT6s were extremely variable (y axis scales vary from panel to 
panel and some of the apparent, magnified peaks/oscillations may have limited clinical 
significance). No significant cosine fit for the aMT6s rhythm could be detected in any patient at 
baseline, or during hospitalization, in either room type. However, two patients showed some degree 
of phase advance on visual analysis [panel D: the nadir of an extremely delayed and weak rhythm 
seems to shift backwards from 20:00 to 16:00 hr (arrow) on the day 7 compared to baseline 
collection; panel G: aMT6s levels increase in a more physiological fashion during the night 
(arrow) on the day 7 compared to baseline collection]; both patients were admitted in the controlled 
lighting system room.  
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